B8FK — Biofrontera AG Balance Sheet
0.000.00%
- €16.47m
- €13.54m
- €21.67m
- 32
- 65
- 63
- 52
Annual balance sheet for Biofrontera AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 17.1 | 6.96 | 7.25 | 4.64 | 3.33 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.51 | 1.52 | 2.22 | 7.36 | 6.68 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 26.1 | 14.4 | 15.1 | 17.7 | 16.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5.05 | 2.28 | 3.01 | 3.29 | 2.93 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 56.4 | 76.7 | 32.7 | 30.7 | 29.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 8.29 | 17.5 | 8.39 | 10.1 | 10.5 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 49 | 18.7 | 12.4 | 10.8 | 10.8 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 7.38 | 58 | 20.3 | 20 | 18.9 |
| Total Liabilities & Shareholders' Equity | 56.4 | 76.7 | 32.7 | 30.7 | 29.7 |
| Total Common Shares Outstanding |